A major moment in India’s fight against type-2 diabetes arrived this week with the launch of Ozempic, the globally popular semaglutide drug known for its strong effects on blood sugar control and weight loss. Doctors, pharma companies and the wider public are already calling it a milestone for metabolic health.

The weekly injectable drug manufactured by Novo Nordisk has entered the market at a starting price of Rs 2,200 per 0.25 mg dose, or around Rs 8,800 for the starting month, making it one of the more accessible GLP-1 medications launched in India so far.

Experts cheer its efficacy, but concerns follow close behind

Several leading endocrinologists welcomed Ozempic’s entry.

Dr Mohan emphasised that the drug represents “science-driven care with patient-centred results,” noting that m

See Full Page